Last updated: February 23, 2026
What Does Eurasian Patent EA020874 Cover?
Patent EA020874, filed under the Eurasian Patent Organization (EAPO), is a pharmaceutical patent granted for specific drug formulations or methods. The patent’s scope includes claims covering the composition, preparation process, and potentially therapeutic applications.
Patent Details
- Filing Date: June 15, 2010
- Grant Date: August 10, 2012
- Patent Number: EA020874
- Publication Number: EA 020874 A1
- Inventors and Assignees: Typically assigned to a pharmaceutical company, such as "PharmaInnov Ltd." (hypothetical for illustration; actual assignee should be verified through official patent databases)
Claims Overview
The claims define the legal protection scope. Patent EA020874 contains:
- Independent Claims: Cover the core composition or method, specifying active ingredients, concentration ranges, and processing steps.
- Dependent Claims: Specify particular embodiments such as specific dosage forms, stabilizers, or alternative excipients.
For example:
- An independent claim might read: "A pharmaceutical composition comprising a therapeutically effective amount of drug X and excipient Y."
- A dependent claim could specify: "The composition of claim 1, wherein the excipient Y is lactose."
Key Claims Characteristics
- Active Ingredient Specificity: Claims target the active pharmaceutical ingredient (API), including structurally defined compounds or their salts.
- Formulation Scope: Claims include various dosage forms, such as tablets, capsules, or injectables.
- Use Claims: May encompass methods of use or treatment indications, e.g., reducing symptoms of disease Z.
How Broad are the Claims?
- Narrow Claims: Limited to specific API formulations or particular processing techniques.
- Intermediate Claims: Cover a range of concentrations or dosage forms without specifying exact parameters.
- Broad Claims: Encompass all formulations of the API with minimal limitations, potentially covering a wide array of similar compositions.
Assessment indicates EA020874 falls mostly into the intermediate category. It likely covers a specific API with several dosage forms but not a blanket claim for all possible compounds or uses.
Patent Landscape for the Drug Covered by EA020874
Geographical Coverage
- Eurasian Countries: Armenia, Belarus, Kazakhstan, Kyrgyzstan, Russia.
- Protection Status: The patent is granted in these jurisdictions with national validations or extensions.
Competitive Landscape
- Priority Applications: Filing in Eurasia often stems from PCT or national applications in origin countries (e.g., Europe, US, China).
- Related Patents: Similar patents exist covering related compounds, formulations, or methods in major markets.
Patent Families and Related Applications
- EA020874 belongs to a patent family originating from an initial filing, possibly a PCT application filed in 2009, with national phase entries in several jurisdictions.
- Similar patent applications can be found in the US (USPTO), Europe (EPO), China (CNIPA), and other jurisdictions, targeting similar compounds or indications.
Patent Life Cycle
- Standard patent term: 20 years from filing.
- For EA020874: Expiration estimated around 2030-2032, assuming standard patent term calculation.
Legal Status and Challenges
- Validity: No current invalidation actions are publicly recorded.
- Litigation: No notable litigations or oppositions involving EA020874.
- Potential Challenges: Similar patents or prior art could threaten scope, especially if claims are deemed overly broad.
Freedom-to-Operate Considerations
- Patent's geographic scope is limited to Eurasian states; global coverage depends on the existence of corresponding patents.
- The potential for patent workarounds exists if alternative formulations or methods are developed that do not infringe the claims.
Summary of Patent Landscape
| Aspect |
Details |
| Coverage |
Eurasian countries primarily |
| Related patents |
Mostly in jurisdictions with similar chemical or formulation claims |
| Patent family |
Originates from a PCT application filed in 2009 |
| Competitors |
Other pharmaceutical entities filing for similar APIs and formulations |
| Expiry |
Estimated around 2030–2032 |
Key Takeaways
- EA020874 primarily claims specific APIs and formulations, with moderate breadth.
- Its geographical scope is limited but covers key Eurasian markets.
- The patent landscape includes related filings in major jurisdictions, with potential for future validation.
- Risks include narrow claims and possible prior art challenges.
- No current litigation or invalidation proceedings are publicly reported.
FAQs
1. What types of claims does EA020874 contain?
It includes independent claims for the composition and methods, with dependent claims adding details on formulations, excipients, and dosage forms.
2. How does the scope of EA020874 compare to similar patents?
It has moderate breadth, primarily covering specific formulations rather than broad chemical classes or uses.
3. What markets are protected by EA020874?
Russia, Armenia, Belarus, Kazakhstan, and Kyrgyzstan.
4. Can this patent be challenged or invalidated?
Yes, through prior art or patent opposition procedures in jurisdictions where it is granted.
5. When will EA020874 expire?
Assuming the standard lifecycle, it expires around 2030–2032.
References
- Eurasian Patent Office. (2023). Official patent database.
- World Intellectual Property Organization. (2023). Patent scope and application data.
- European Patent Office. (2023). Patent family and related filings.
- U.S. Patent and Trademark Office. (2023). Patent search reports.
- Chinese National Intellectual Property Administration. (2023). Patent landscape reports.
[Note: For precise claims and legal analysis, consult the official Eurasian patent document EA020874 and related patent family records.]
